%D8%B9%D9%84%D8%A7%D8%AC_%D9%85%D9%88%D8%AC%D9%87Gezielte_KrebstherapieTargeted_therapyTerapia_dirigidaTh%C3%A9rapeutique_cibl%C3%A9eTerapia_dirixida%D7%AA%D7%A8%D7%95%D7%A4%D7%94_%D7%91%D7%99%D7%95%D7%9C%D7%95%D7%92%D7%99%D7%AAC%C3%A9lzott_molekul%C3%A1ris_daganatter%C3%A1pia%D4%B9%D5%AB%D6%80%D5%A1%D5%AD%D5%A1%D5%B5%D5%AB%D5%B6_%D5%A2%D5%B8%D6%82%D5%AA%D5%B8%D6%82%D5%B4Terapia_mirata%E5%88%86%E5%AD%90%E6%A8%99%E7%9A%84%E6%B2%BB%E7%99%82%ED%91%9C%EC%A0%81_%EC%B9%98%EB%A3%8CTerapia_dirigida%D0%A2%D0%B0%D1%80%D0%B3%D0%B5%D1%82%D0%BD%D0%B0%D1%8F_%D1%82%D0%B5%D1%80%D0%B0%D0%BF%D0%B8%D1%8FTar%C4%8Dno_zdravljenjeCiljana_terapijaM%C3%A5linriktade_cancerl%C3%A4kemedel%E0%B8%81%E0%B8%B2%E0%B8%A3%E0%B8%A3%E0%B8%B1%E0%B8%81%E0%B8%A9%E0%B8%B2%E0%B9%81%E0%B8%9A%E0%B8%9A%E0%B8%A1%E0%B8%B8%E0%B9%88%E0%B8%87%E0%B9%80%E0%B8%9B%E0%B9%89%E0%B8%B2Q492646%E6%A8%99%E9%9D%B6%E6%B2%BB%E7%99%82%E9%9D%B6%E5%90%91%E6%B2%BB%E7%96%97
about
sameAs
P828
Metastatic disease from uveal melanoma: treatment options and future prospectsThe landscape of targeted therapies for cholangiocarcinoma: current status and emerging targetsTargeted therapy for advanced gastric cancer: A review of current status and future prospectsThe Impact of Genomic Profiling for Novel Cancer Therapy--Recent Progress in Non-Small Cell Lung CancerFluorescence in situ hybridization in surgical pathology: principles and applications.The role of targeted agents in the adjuvant treatment of colon cancer: a meta-analysis of randomized phase III studies and reviewA phase II evaluation of cediranib in the treatment of recurrent or persistent endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study.Identifying therapeutic targets in gastric cancer: the current status and future directionUnusual presentations of melanoma: melanoma of unknown primary site, melanoma arising in childhood, and melanoma arising in the eye and on mucosal surfaces.Epigenetic Targeted Therapy for Diffuse Intrinsic Pontine GliomaUnderstanding the Role of Non-Coding RNAs in Bladder Cancer: From Dark Matter to Valuable Therapeutic Targets.Medulloblastoma in children and adolescents: a systematic review of contemporary phase I and II clinical trials and biology update.Analyses of repeated failures in cancer therapy for solid tumors: poor tumor-selective drug delivery, low therapeutic efficacy and unsustainable costs.Novel Application of Metformin Combined with Targeted Drugs on Anticancer TreatmentFibroblast growth factor receptor 1 (FGFR1) as a therapeutic target in adenoid cystic carcinoma of the lacrimal glandSustained response of three pediatric BRAF mutated high-grade gliomas to combined BRAF and MEK inhibitor therapyBilateral spontaneous pneumothoraces in anaplastic thyroid cancerROS1-GOPC/FIG: a novel gene fusion in hepatic angiosarcomaResistances to tyrosine kinase inhibitors in lung cancer-how to routinely track them in a molecular pathology laboratory?Targeted Therapy and Immunotherapy for Melanoma in JapanMolecular pathways of oral cancer that predict prognosis and survival: A systematic reviewEvolution of Relapse-Proficient Subclones Constrained by Collateral Sensitivity to Oncogene Overdose in Wnt-Driven Mammary CancerTumor Tissue Explant Culture of Patient-Derived Xenograft as Potential Prioritization Tool for Targeted TherapyTargeted therapy in ovarian cancerWobble uridine tRNA modification: a new vulnerability of refractory melanomaHuman epidermal growth factor receptor 2 amplification as a biomarker for treatment in patients with lymph node-metastatic penoscrotal extramammary Paget's diseaseOutcome of chemotherapy with or without targeted agents in metastatic colorectal cancer patients with deficient DNA mismatch repair: A single center, cohort studyPhosphatidylinositol 3-kinase pathway genomic alterations in 60,991 diverse solid tumors informs targeted therapy opportunitiesRecent advances in the management of systemic lupus erythematosusTales of Personalized Cancer TreatmentTubulocystic Renal Cell Carcinoma: A Great ImitatorNovel Therapies and Approaches to Relapsed/Refractory HL Beyond ChemotherapyWerner syndrome helicase is a selective vulnerability of microsatellite instability-high tumor cellsPD-L1 expression and tumor mutational burden status for prediction of response to chemotherapy and targeted therapy in non-small cell lung cancerPreclinical validation of 3-phosphoinositide-dependent protein kinase 1 inhibition in pancreatic cancerTargeting Microglia and Macrophages: A Potential Treatment Strategy for Multiple SclerosisImpact of ERK5 on the Hallmarks of CancerQuizartinib (AC220): a promising option for acute myeloid leukemiaTargeting Molecular Pathways in Intracranial Metastatic DiseaseDirect use of eazyplex SuperBug CRE assay from positive blood cultures in conjunction with inpatient infectious disease consulting for timely appropriate antimicrobial therapy in and bloodstream infections
P921
Q26738377-c7d94f7a-4666-6935-fc8b-24c98b66feffQ26751224-238f96b3-4121-4d46-1d6e-9635afde9f95Q26774138-B38CB7A9-768F-4636-8E31-DDF05335B91EQ28067196-B5DD847E-AE7E-4292-876E-5EAAD7A83199Q33593910-F441FB42-19CD-4BDB-A106-E4E3A9F2D7C1Q33761655-44c6bc6c-4569-1d24-0737-a1452b99d218Q36274386-16FB30C4-971C-476B-8229-D978AD3DCF15Q36398732-DB3B0EE5-051C-45C3-8C05-E956B4AFC613Q38253276-C056BC56-DBDA-448F-ABE3-1241FAB9AB25Q39154575-bb179be8-4b5f-6154-8613-d7252d6e779bQ39432577-121ed389-406f-2ea1-f7c6-c148a5d0ae3eQ47133403-b27eb771-4077-0cbb-6ba4-d468380ac7cdQ51763013-1CDF9B8E-C968-4E71-91F5-B4A8EF22A641Q57784984-7dadc2a0-4203-a71f-a6da-531030ff070aQ61796798-0E1BB6E5-005C-4D78-BB5E-C5B34127837FQ61796808-C742AF5F-2DC6-4995-A06C-D995FFBA1211Q61803751-F742BEA7-1402-4946-B9A3-2E6B85844F55Q61806358-B784C6EB-5343-4287-8AA0-B2CE540914FCQ61810145-C27B4DBD-0173-4DE5-85CF-19D59E025DC8Q61810153-A0CC96F1-6872-4BD1-BA01-4799608E9DB4Q61810949-BFAC8586-2B4A-4E61-8BF0-EB1B7303DBEDQ61811551-2E5ABFC0-800A-40BA-851B-463162BB6752Q61811720-2EBD49D8-A4F3-4D59-9EB1-09151ACFE7FBQ63359576-CFB569FB-CA6B-4A82-B19B-D48C7D18D6FBQ63979904-475C0768-8905-42CF-ADDA-6DCFF043EDFFQ64039988-BC2B69E6-E3BD-472C-A25D-A70D5DA49463Q64041030-BFA3EC40-4A37-4B2D-A08E-2EA428F46E5DQ64041783-E2B4FA7F-084A-4AE8-9E6A-12DE79423453Q64044243-25924374-3535-40EF-AB34-96B3DA63D434Q64047654-AEDF3693-CCF6-4049-B617-2158C8C8920DQ64047961-6683F6F3-CC08-4658-A8FC-7D62EE200B06Q64054421-FE3A083D-8EFE-4E3F-825C-4899F7DF183EQ64054862-F43E49AC-062B-4F16-8803-4663DA7D99EDQ64056211-4BC85E33-25EF-4F30-8A5B-CD9F6B831A9EQ64056226-1A6D1EC3-0BE7-4DC1-8605-0CA4EDAA9341Q64061544-2DA82846-DA71-4C02-960C-FE11B608E585Q64065870-ED59CFFF-1028-4DAF-AD66-234B3FF183F0Q64066440-75AD48F8-B6F6-4B33-873D-240135A0C9ECQ64067749-C9B3E712-1F95-4EC1-8675-8A1650CD1B61Q64068480-3AC8AC09-7497-4410-ACA2-29EB136BCF19
P921
description
drug treatment which interacts ...... in progression of the disease
@en
farmacoterapia para el cáncer
@es
médicaments qui ciblent spécifiquement un mécanisme de la tumeur
@fr
terapia farmacologica per la cura dei tumori
@it
typ av läkemedelsbehandling mot cancer
@sv
一種以干擾癌變或腫瘤增生所需的特定分子來阻止癌細胞增長的一種藥物療法
@zh
name
Ciljana terapija
@sr
Liệu pháp trúng đích
@vi
Målinriktade cancerläkemedel
@sv
Tarčno zdravljenje
@sl
Terapia dirixida
@gl
celata terapio
@eo
célzott molekuláris daganatterápia
@hu
gezielte Krebstherapie
@de
targeted therapy
@en
terapia dirigida
@es
type
label
Ciljana terapija
@sr
Liệu pháp trúng đích
@vi
Målinriktade cancerläkemedel
@sv
Tarčno zdravljenje
@sl
Terapia dirixida
@gl
celata terapio
@eo
célzott molekuláris daganatterápia
@hu
gezielte Krebstherapie
@de
targeted therapy
@en
terapia dirigida
@es
altLabel
Molecularly-targeted therapy
@en
Targeted therapy
@de
Targeted therapy
@th
molecular targeted therapy
@en
terapia dirigida molecularmente
@es
分子標的治療薬
@ja
分子標的薬
@ja
prefLabel
Ciljana terapija
@sr
Liệu pháp trúng đích
@vi
Målinriktade cancerläkemedel
@sv
Tarčno zdravljenje
@sl
Terapia dirixida
@gl
celata terapio
@eo
célzott molekuláris daganatterápia
@hu
gezielte Krebstherapie
@de
targeted therapy
@en
terapia dirigida
@es
P486
P6366
P646
P672
P1417
topic/targeted-therapy
P1542
P279
P486
P6366
2781230642
2908853286
P646
P672
E02.319.574